A detailed history of Blair William & CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 312 shares of HALO stock, worth $19,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares
312
Holding current value
$19,443
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$37.81 - $52.4 $11,796 - $16,348
312 New
312 $16,000
Q4 2022

Feb 10, 2023

SELL
$40.06 - $59.44 $78,517 - $116,502
-1,960 Reduced 11.55%
15,017 $854,000
Q3 2022

Nov 09, 2022

SELL
$38.53 - $51.78 $3,698 - $4,970
-96 Reduced 0.56%
16,977 $671,000
Q2 2022

Aug 10, 2022

SELL
$37.35 - $48.3 $112,983 - $146,107
-3,025 Reduced 15.05%
17,073 $751,000
Q1 2022

May 13, 2022

SELL
$31.97 - $41.06 $4,891 - $6,282
-153 Reduced 0.76%
20,098 $802,000
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $1,081 - $1,385
34 Added 0.17%
20,251 $814,000
Q3 2021

Nov 12, 2021

BUY
$38.47 - $46.42 $29,429 - $35,511
765 Added 3.93%
20,217 $822,000
Q2 2021

Aug 12, 2021

SELL
$38.84 - $51.31 $68,008 - $89,843
-1,751 Reduced 8.26%
19,452 $883,000
Q1 2021

May 13, 2021

SELL
$39.51 - $51.45 $119,517 - $155,636
-3,025 Reduced 12.49%
21,203 $884,000
Q4 2020

Feb 09, 2021

SELL
$25.81 - $43.62 $65,092 - $110,009
-2,522 Reduced 9.43%
24,228 $1.04 Million
Q3 2020

Nov 06, 2020

SELL
$25.74 - $29.63 $28,725 - $33,067
-1,116 Reduced 4.0%
26,750 $703,000
Q2 2020

Aug 12, 2020

BUY
$16.25 - $26.81 $23,611 - $38,954
1,453 Added 5.5%
27,866 $747,000
Q1 2020

May 11, 2020

BUY
$13.9 - $21.83 $69,083 - $108,495
4,970 Added 23.18%
26,413 $475,000
Q4 2019

Feb 13, 2020

BUY
$14.93 - $19.53 $320,143 - $418,781
21,443 New
21,443 $380,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.68B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.